Robotic Surgery for Biliary Tract Cancer

被引:13
|
作者
Kone, Lyonell B. [1 ]
Bystrom, Philip V. [1 ]
Maker, Ajay V. [2 ]
机构
[1] Univ Illinois, Metropolitan Grp Hosp, Chicago, IL 60607 USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
关键词
cholangiocarcinoma; gallbladder cancer; robotic surgery; biliary tract cancer; klatskin tumor; minimally invasive surgery; HILAR CHOLANGIOCARCINOMA; GALLBLADDER CANCER; RADICAL RESECTION; OUTCOMES;
D O I
10.3390/cancers14041046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Complete surgical resection of biliary tract cancer provides the best chance at long-term survival. These surgeries are complex and can be associated with high morbidity and prolonged recovery. Minimally invasive approaches have been shown to improve some of these outcomes in other cancers. However, there is a paucity of data in biliary cancer, and even less is known about the outcomes of surgery utilizing a robotic platform. The present review reports the pooled outcomes of robotic surgery for 259 patients with biliary tract cancer. These outcomes are often equivalent to or improved compared to contemporary data on open surgery. The published data lack prospective or randomized studies. Thus, to evaluate any of the potential benefits of robotic surgery for biliary tract cancer, higher-quality studies are needed. Biliary tract cancer consists of cholangiocarcinoma (CC) and gallbladder cancer (GBC). When resectable, surgery provides the best chance at long-term survival. Unfortunately, surgery for these tumors is associated with long operative times, high morbidities, and prolonged hospital stays. Minimally invasive surgery has been shown to impact selected outcomes, including length of stay, in other diseases, and robotic surgery may offer additional advantages compared to laparoscopic surgery in treating bile duct cancers. This is a systematic review of robotic surgery for biliary tract cancer. Predetermined selection criteria were used to appraise the literature. The PRISMA guidelines were followed. In total, 20 unique articles with a total of 259 patients with biliary tract cancer undergoing robotic surgery met the inclusion criteria. For CC and GBC, respectively, the weighted average operative time was 401 and 277 min, the estimated blood loss was 348 and 260 mL, the conversion rate to open was 7 and 3.5%, the all-cause morbidity was 52 and 9.7%, the major morbidity was 12 and 4.4%, the perioperative mortality was 1.4 and 0%, the length of stay was 15 and 4.8 days, the positive margin rate was 27 and 9%, and the number of lymph nodes retrieved was 4.2 and 8. Robotic surgery for biliary tract cancer appears non-inferior to open surgery when compared to the published contemporary data. However, the current literature on the topic is of low quality, and future prospective/randomized studies are needed.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Biliary Tract Cancer: Molecular Biology of Precursor Lesions
    Manzano-Nunez, Fatima
    Aguilar, Lara Prates Tiago
    Sempoux, Christine
    Lemaigre, Frederic P.
    SEMINARS IN LIVER DISEASE, 2023, 43 (04) : 472 - 484
  • [42] Changing Landscape of Systemic Therapy in Biliary Tract Cancer
    Woods, Edward
    Le, Dat
    Jakka, Bharath Kumar
    Manne, Ashish
    CANCERS, 2022, 14 (09)
  • [43] Current and Future Systemic Therapies in Biliary Tract Cancer
    Vogel, Arndt
    Saborowski, Anna
    VISCERAL MEDICINE, 2021, 37 (01) : 32 - 38
  • [44] Immunotherapeutic Approaches to Biliary Cancer
    Shah, Urvi A.
    Nandikolla, Amara G.
    Rajdev, Lakshmi
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (07)
  • [45] Dysbiosis of the Fecal and Biliary Microbiota in Biliary Tract Cancer
    Ito, Zensho
    Koido, Shigeo
    Kato, Kumiko
    Odamaki, Toshitaka
    Horiuchi, Sankichi
    Akasu, Takafumi
    Saruta, Masayuki
    Hata, Taigo
    Kumagai, Yu
    Fujioka, Shuichi
    Misawa, Takeyuki
    Xiao, Jin-zhong
    Sato, Nobuhiro
    Ohkusa, Toshifumi
    CANCERS, 2022, 14 (21)
  • [46] HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer
    Vivaldi, Caterina
    Fornaro, Lorenzo
    Ugolini, Clara
    Niccoli, Cristina
    Musettini, Gianna
    Pecora, Irene
    Cacciato Insilla, Andrea
    Salani, Francesca
    Pasquini, Giulia
    Catanese, Silvia
    Lencioni, Monica
    Masi, Gianluca
    Campani, Daniela
    Fontantini, Gabriella
    Falcone, Alfredo
    Vasile, Enrico
    ONCOLOGIST, 2020, 25 (10) : 886 - 893
  • [47] Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer
    Hong, Yong Sang
    Lee, Jeeyun
    Lee, Sang Cheol
    Hwang, In Gyu
    Choi, Seong-Ho
    Heo, Jin-Seok
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (03) : 321 - 328
  • [48] Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer
    Yong Sang Hong
    Jeeyun Lee
    Sang Cheol Lee
    In Gyu Hwang
    Seong-Ho Choi
    Jin-Seok Heo
    Joon Oh Park
    Young Suk Park
    Ho Yeong Lim
    Won Ki Kang
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 321 - 328
  • [49] Adjuvant therapy of biliary tract cancers
    Kefas, Joanna
    Bridgewater, John
    Vogel, Arndt
    Stein, Alexander
    Primrose, John
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [50] Robotic Surgery for Cancer
    Ohuchida, Kenoki
    Hashizume, Makoto
    CANCER JOURNAL, 2013, 19 (02) : 130 - 132